Search Results for "hATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Exploratory Biomarker Analyses from HELIOS-B, A Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Patisiran: Cardiac Results from the APOLLO Study

Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy

This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Vutrisiran: Survival and Mortality

Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.

Primary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis

Patisiran: APOLLO-B OLE Study

Standard response letter on the APOLLO-B OLE study of patisiran.

Exploratory Analyses from APOLLO-B, A Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.